Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | CCR8 | P51685 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183373 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19SLC5A2P4HTM | |
| SCHEMBL19135074 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19SLC5A2P4HTM | |
| SCHEMBL14533667 | 0.79 | PIM1 (0.35) | SLC5A2LMNAHIF1ATP53HTT | |
| SCHEMBL14507291 | 0.79 | PIM1 (0.35) | SLC5A2LMNAHIF1ATP53HTT | |
| SCHEMBL15129319 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL14391672 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL10183381 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL19135285 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL14533671 | 0.76 | CYP2A6 (0.58) | POLBSMN1; SMN2CYP2A6 | |
| SCHEMBL5878277 | 0.76 | CYP2A6 (0.58) | POLBSMN1; SMN2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2017-10-05 | — | — | US | disclosed |
| US-9708615-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2216407-B1 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9222091-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140316124-A1 | MODIDIFED iRNA AGENTS | BANK OF AMERICA, N.A. | 2014-10-23 | — | — | US | disclosed |
| US-20140316124-A1 | MODIDIFED iRNA AGENTS | BANK OF AMERICA, N.A. | 2014-10-23 | — | — | US | disclosed |
| US-20140309411-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2014-10-16 | — | — | US | disclosed |
| US-20130144048-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130144048-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8445665-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8420799-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1615611-B1 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | CYP1A2 4840/4885CYP2C9 4885/4885CYP2C19 4884/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | CYP1A2 4371/4885CYP2C9 4650/4885CYP2C19 4431/4885 |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-20130144048-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | CYP1A2 2684/4885CYP2C9 3809/4885CYP2C19 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.